Alessandro A E Testori

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8945256/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC). Annals of Surgical Oncology, 2022, 29, 3694-3708.	1.5	21
2	Preoperative Ultrasound Assessment of Regional Lymph Nodes in Melanoma Patients Does not Provide Reliable Nodal Staging. Annals of Surgery, 2021, 273, 814-820.	4.2	16
3	Real Life Clinical Management and Survival in Advanced Cutaneous Melanoma: The Italian Clinical National Melanoma Registry Experience. Frontiers in Oncology, 2021, 11, 672797.	2.8	2
4	Letter to the European Dermatology Forum, the European Association of Dermato-Oncology and the European Organization for Research and Treatment of Cancer on guidelines on basal cell carcinoma. European Journal of Cancer, 2020, 140, 151-153.	2.8	1
5	Adjuvant Therapy for Melanoma: Past, Current, and Future Developments. Cancers, 2020, 12, 1994.	3.7	26
6	Adjuvant therapy with pegylated interferon-alfa2b vs observation in stage II B/C patients with ulcerated primary: Results of the European Organisation for Research and Treatment of Cancer 18081 randomised trial. European Journal of Cancer, 2020, 133, 94-103.	2.8	13
7	The EORTC-DeCOG nomogram adequately predicts outcomes of patients with sentinel node–positive melanoma without the need for completion lymph node dissection. European Journal of Cancer, 2020, 134, 9-18.	2.8	11
8	Prognosis of Patients With Stage III Melanoma According to American Joint Committee on Cancer Version 8: A Reassessment on the Basis of 3 Independent Stage III Melanoma Cohorts. Journal of Clinical Oncology, 2020, 38, 2543-2551.	1.6	40
9	The Great Debate at "Melanoma Bridgeâ€, Naples, December 7th, 2019. Journal of Translational Medicine, 2020, 18, 171.	4.4	2
10	Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial. European Journal of Cancer, 2019, 119, 1-10.	2.8	132
11	Surgery for Metastatic Melanoma: an Evolving Concept. Current Oncology Reports, 2019, 21, 98.	4.0	11
12	Adjuvant Treatment of Melanoma: Recent Developments and Future Perspectives. American Journal of Clinical Dermatology, 2019, 20, 817-827.	6.7	29
13	Primary Melanoma: from History to Actual Debates. Current Oncology Reports, 2019, 21, 112.	4.0	8
14	Risk stratification of sentinel node–positive melanoma patients defines surgical management and adjuvant therapy treatment considerations. European Journal of Cancer, 2018, 96, 25-33.	2.8	59
15	Lymph node ratio as a prognostic factor in melanoma: results from European Organization for Research and Treatment of Cancer 18871, 18952, and 18991 studies. Melanoma Research, 2018, 28, 222-229.	1.2	5
16	MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2018, 19, 916-929.	10.7	131
17	Germline polymorphisms of the VEGF-pathway predict recurrence in non-advanced differentiated thyroid cancer. Journal of Clinical Endocrinology and Metabolism, 2017, 102, jc.2016-2555.	3.6	23
18	Pregnancy and melanoma: a Europeanâ€wide survey to assess current management and a critical literature overview. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 65-69.	2.4	18

#	Article	IF	CITATIONS
19	Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial. Lancet Oncology, The, 2017, 18, 393-403.	10.7	91
20	Ipilimumab Adjuvant Therapy in Melanoma. New England Journal of Medicine, 2017, 376, 398-399.	27.0	7
21	The Impact of Smoking on Sentinel Node Metastasis of Primary Cutaneous Melanoma. Annals of Surgical Oncology, 2017, 24, 2089-2094.	1.5	22
22	Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma. New England Journal of Medicine, 2017, 376, 2211-2222.	27.0	1,087
23	Preliminary data of VEGF-A and VEGFR-2 polymorphisms as predictive factors of radiological response and clinical outcome in iodine-refractory differentiated thyroid cancer treated with sorafenib. Endocrine, 2017, 57, 539-543.	2.3	10
24	Learning from mistakes: errors in approaches to melanoma and the urgent need for updated national guidelines. International Journal of Dermatology, 2016, 55, 970-976.	1.0	7
25	Treatment efficacy with electrochemotherapy: A multi-institutional prospective observational study on 376 patients with superficial tumors. European Journal of Surgical Oncology, 2016, 42, 1914-1923.	1.0	89
26	Unknown Primary Melanoma: Worldwide Survey on Clinical Management. Dermatology, 2016, 232, 704-707.	2.1	20
27	<i>In Vivo</i> Genetic Screens of Patient-Derived Tumors Revealed Unexpected Frailty of the Transformed Phenotype. Cancer Discovery, 2016, 6, 650-663.	9.4	59
26			
20	Sun exposure and melanoma prognostic factors. Oncology Letters, 2016, 11, 2706-2714.	1.8	29
29	Sun exposure and melanoma prognostic factors. Oncology Letters, 2016, 11, 2706-2714. BCAM and LAMA5 Mediate the Recognition between Tumor Cells and the Endothelium in the Metastatic Spreading of KRAS-Mutant Colorectal Cancer. Clinical Cancer Research, 2016, 22, 4923-4933.	1.8 7.0	29 50
29 30	Sun exposure and melanoma prognostic factors. Oncology Letters, 2016, 11, 2706-2714. BCAM and LAMA5 Mediate the Recognition between Tumor Cells and the Endothelium in the Metastatic Spreading of KRAS-Mutant Colorectal Cancer. Clinical Cancer Research, 2016, 22, 4923-4933. Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. New England Journal of Medicine, 2016, 375, 1845-1855.	1.8 7.0 27.0	29 50 1,140
29 30 31	Sun exposure and melanoma prognostic factors. Oncology Letters, 2016, 11, 2706-2714. BCAM and LAMA5 Mediate the Recognition between Tumor Cells and the Endothelium in the Metastatic Spreading of KRAS-Mutant Colorectal Cancer. Clinical Cancer Research, 2016, 22, 4923-4933. Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. New England Journal of Medicine, 2016, 375, 1845-1855. Multiple primary melanomas (MPMs) and criteria for genetic assessment: MultiMEL, a multicenter study of the Italian Melanoma Intergroup. Journal of the American Academy of Dermatology, 2016, 74, 325-332.	1.8 7.0 27.0 1.2	29 50 1,140 32
29 30 31 32	Sun exposure and melanoma prognostic factors. Oncology Letters, 2016, 11, 2706-2714. BCAM and LAMA5 Mediate the Recognition between Tumor Cells and the Endothelium in the Metastatic Spreading of KRAS-Mutant Colorectal Cancer. Clinical Cancer Research, 2016, 22, 4923-4933. Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. New England Journal of Medicine, 2016, 375, 1845-1855. Multiple primary melanomas (MPMs) and criteria for genetic assessment: MultiMEL, a multicenter study of the Italian Melanoma Intergroup. Journal of the American Academy of Dermatology, 2016, 74, 325-332. Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB–III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation: Ulceration of primary is key determinant for IFN-sensitivity. European Journal of Cancer, 2016, 55, 111-121	1.8 7.0 27.0 1.2 2.8	29 50 1,140 32 80
29 30 31 32 33	Sun exposure and melanoma prognostic factors. Oncology Letters, 2016, 11, 2706-2714. BCAM and LAMA5 Mediate the Recognition between Tumor Cells and the Endothelium in the Metastatic Spreading of KRAS-Mutant Colorectal Cancer. Clinical Cancer Research, 2016, 22, 4923-4933. Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. New England Journal of Medicine, 2016, 375, 1845-1855. Multiple primary melanomas (MPMs) and criteria for genetic assessment: MultiMEL, a multicenter study of the Italian Melanoma Intergroup. Journal of the American Academy of Dermatology, 2016, 74, 325-332. Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB–III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation: Ulceration of primary is key determinant for IFN-sensitivity. European Journal of Cancer, 2016, 55, 111-121. Dacarbazine in combination with bevacizumab for the treatment of unresectable/metastatic melanoma. Melanoma Research, 2015, 25, 239-245.	1.8 7.0 27.0 1.2 2.8 1.2	29 50 1,140 32 80 23
29 30 31 32 33 34	Sun exposure and melanoma prognostic factors. Oncology Letters, 2016, 11, 2706-2714. BCAM and LAMA5 Mediate the Recognition between Tumor Cells and the Endothelium in the Metastatic Spreading of KRAS-Mutant Colorectal Cancer. Clinical Cancer Research, 2016, 22, 4923-4933. Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. New England Journal of Medicine, 2016, 375, 1845-1855. Multiple primary melanomas (MPMs) and criteria for genetic assessment: MultiMEL, a multicenter study of the Italian Melanoma Intergroup. Journal of the American Academy of Dermatology, 2016, 74, 325-332. Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB–III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation: Ulceration of primary is key determinant for IFN-sensitivity. European Journal of Cancer, 2016, 55, 111-121. Dacarbazine in combination with bevacizumab for the treatment of unresectable/metastatic melanoma. Melanoma Research, 2015, 25, 239-245. Combined approach for the biomechanical characterization of skin lesions., 2015, 2015, 913-6.	1.8 7.0 27.0 1.2 2.8 1.2	29 50 1,140 32 80 23 0
29 30 31 32 33 33 34 35	Sun exposure and melanoma prognostic factors. Oncology Letters, 2016, 11, 2706-2714. BCAM and LAMA5 Mediate the Recognition between Tumor Cells and the Endothelium in the Metastatic Spreading of KRAS-Mutant Colorectal Cancer. Clinical Cancer Research, 2016, 22, 4923-4933. Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. New England Journal of Medicine, 2016, 375, 1845-1855. Multiple primary melanomas (MPMs) and criteria for genetic assessment: MultiMEL, a multicenter study of the Italian Melanoma Intergroup. Journal of the American Academy of Dermatology, 2016, 74, 325-332. Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB–III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation: Ulceration of primary is key determinant for IFN-sensitivity. European Journal of Cancer, 2016, 55, 111-121. Dacarbazine in combination with bevacizumab for the treatment of unresectable/metastatic melanoma. Melanoma Research, 2015, 25, 239-245. Combined approach for the biomechanical characterization of skin lesions. , 2015, 2015, 913-6. Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline. European Journal of Cancer, 2015, 51, 1989-2007.	1.8 7.0 27.0 1.2 2.8 1.2 2.8	29 50 1,140 32 80 23 0 404

#	Article	IF	CITATIONS
37	Report from the second MIB (Melanoma Independent Board) Conference, 27–28 October 2014. Ecancermedicalscience, 2015, 9, 511.	1.1	0

Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC) Tj ETQq0 0 0 rgBT /Overlock 10 Tf

39	Five-Year Survival Rates for Treatment-Naive Patients With Advanced Melanoma Who Received Ipilimumab Plus Dacarbazine in a Phase III Trial. Journal of Clinical Oncology, 2015, 33, 1191-1196.	1.6	445
40	Diagnosis and treatment of Merkel Cell Carcinoma. European consensus-based interdisciplinary guideline. European Journal of Cancer, 2015, 51, 2396-2403.	2.8	320
41	EANM practice guidelines for lymphoscintigraphy and sentinel lymph node biopsy in melanoma. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1750-1766.	6.4	110
42	Skin-directed electrochemotherapy: A prospective multi-institutional study on 394 patients with superficial tumors Journal of Clinical Oncology, 2015, 33, e20001-e20001.	1.6	0
43	Sequential Treatment with Ipilimumab and BRAF Inhibitors in Patients With Metastatic Melanoma: Data From the Italian Cohort of the Ipilimumab Expanded Access Program. Cancer Investigation, 2014, 32, 144-149.	1.3	90
44	Treatment of metastatic melanoma with electrochemotherapy. Journal of Surgical Oncology, 2014, 109, 301-307.	1.7	45
45	The risk of developing a second primary cancer in melanoma patients: A comprehensive review of the literature and meta-analysis. Journal of Dermatological Science, 2014, 75, 3-9.	1.9	66
46	Heat-shock proteins-based immunotherapy for advanced melanoma in the era of target therapies and immunomodulating agents. Expert Opinion on Biological Therapy, 2014, 14, 955-967.	3.1	20
47	Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme. Journal of Experimental and Clinical Cancer Research, 2014, 33, 30.	8.6	97
48	Clinical experience with ipilimumab 3Âmg/kg: real-world efficacy and safety data from an expanded access programme cohort. Journal of Translational Medicine, 2014, 12, 116.	4.4	149
49	Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncology, The, 2014, 15, 323-332.	10.7	890
50	Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma. European Journal of Cancer, 2014, 50, 121-127.	2.8	149
51	Maspin expression and melanoma progression: a matter of sub-cellular localization. Modern Pathology, 2014, 27, 412-419.	5.5	16
52	Final overall survival from a phase 3 trial of nab-paclitaxel versus dacarbazine (DTIC) in chemotherapy-naive patients with metastatic melanoma Journal of Clinical Oncology, 2014, 32, 9045-9045.	1.6	3
53	Ipilimumab versus placebo after complete resection of stage III melanoma: Initial efficacy and safety results from the EORTC 18071 phase III trial Journal of Clinical Oncology, 2014, 32, LBA9008-LBA9008.	1.6	14
54	Ipilimumab versus placebo after complete resection of stage III melanoma: Initial efficacy and safety results from the EORTC 18071 phase III trial Journal of Clinical Oncology, 2014, 32, LBA9008-LBA9008.	1.6	32

#	Article	IF	CITATIONS
55	Electrochemotherapy: A treatment with specific intent in specific skin tumors—Experience from the European Institute of Oncology, Milan Journal of Clinical Oncology, 2014, 32, e20042-e20042.	1.6	0
56	Phase I-II study of the combination vemurafenib plus peg-interferon in advanced melanoma patients harboring the V600BRAF mutation Journal of Clinical Oncology, 2014, 32, TPS9105-TPS9105.	1.6	0
57	Brain metastasis in melanoma patients: Associations with <i>BRAF</i> status and age Journal of Clinical Oncology, 2014, 32, e20037-e20037.	1.6	0
58	Sentinel Node Biopsy in Thin and Thick Melanoma. Annals of Surgical Oncology, 2013, 20, 2780-2786.	1.5	72
59	Analysis of surrogate gene expression markers in peripheral blood of melanoma patients to predict treatment outcome of adjuvant pegylated interferon alpha 2b (EORTC 18991 side study). Cancer Immunology, Immunotherapy, 2013, 62, 1223-1233.	4.2	5
60	Whole-body diffusion-weighted imaging: is it all we need for detecting metastases in melanoma patients?. European Radiology, 2013, 23, 3466-3476.	4.5	39
61	Selection of Immunostimulant AS15 for Active Immunization With MAGE-A3 Protein: Results of a Randomized Phase II Study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma. Journal of Clinical Oncology, 2013, 31, 2413-2420.	1.6	188
62	Final Results of Phase III SYMMETRY Study: Randomized, Double-Blind Trial of Elesclomol Plus Paclitaxel Versus Paclitaxel Alone As Treatment for Chemotherapy-Naive Patients With Advanced Melanoma. Journal of Clinical Oncology, 2013, 31, 1211-1218.	1.6	182
63	Pediatric melanoma: Analysis of an international registry. Cancer, 2013, 119, 4012-4019.	4.1	71
64	Follow-Up of Melanoma: A Survey of Italian Hospitals. Dermatology, 2013, 226, 32-38.	2.1	9
65	Surgical Management of Suspicious Melanocytic Lesions in Italy. Dermatology, 2013, 226, 18-21.	2.1	1
66	Management of Small and Intermediate Congenital Nevi: A Nationwide Survey in Italy. Dermatology, 2013, 226, 7-12.	2.1	5
67	Diagnostic and Therapeutic Approaches in Italian Hospitals: Adjuvant and Metastatic Therapy in Melanoma. Dermatology, 2013, 226, 22-27.	2.1	4
68	Impact of Mole Mapping in the Italian Health System. Dermatology, 2013, 226, 13-17.	2.1	2
69	Clinical experience with ipilimumab 10Âmg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme. Journal of Experimental and Clinical Cancer Research, 2013, 32, 82.	8.6	23
70	Surgical Treatment of Melanoma: A Survey of Italian Hospitals. Dermatology, 2013, 226, 28-31.	2.1	21
71	Diagnostic Services for Melanoma in Italy. Dermatology, 2013, 226, 3-6.	2.1	2
72	Melanoma Task Force (META) Project in Italy: Methodology. Dermatology, 2013, 226, 1-2.	2.1	18

Alessandro A E Testori

#	Article	IF	CITATIONS
73	Sunny Holidays before and after Melanoma Diagnosis Are Respectively Associated with Lower Breslow Thickness and Lower Relapse Rates in Italy. PLoS ONE, 2013, 8, e78820.	2.5	13
74	Lenvatinib combined with dacarbazine versus dacarbazine alone as first-line treatment in patients with stage IV melanoma Journal of Clinical Oncology, 2013, 31, 9027-9027.	1.6	3
75	A phase III trial of nab-paclitaxel versus dacarbazine in chemotherapy-naive patients with metastatic melanoma: A subanalysis based on BRAF status Journal of Clinical Oncology, 2013, 31, 9030-9030.	1.6	6
76	Correlation between efficacy and toxicity in pts with pretreated advanced melanoma treated within the Italian cohort of the ipilimumab expanded access programme (EAP) Journal of Clinical Oncology, 2013, 31, 9065-9065.	1.6	12
77	Efficacy and safety data from elderly patients with pretreated advanced melanoma in the Italian cohort of ipilimumab expanded access programme (EAP) Journal of Clinical Oncology, 2013, 31, 9548-9548.	1.6	0
78	Long-Term Results of the Randomized Phase III Trial EORTC 18991 of Adjuvant Therapy With Pegylated Interferon Alfa-2b Versus Observation in Resected Stage III Melanoma. Journal of Clinical Oncology, 2012, 30, 3810-3818.	1.6	254
79	Utility of electrochemotherapy in melanoma treatment. Current Opinion in Oncology, 2012, 24, 155-161.	2.4	34
80	Ipilimumab Targeting CD28-CTLA-4 Axis: New Hope in the Treatment of Melanoma. Current Topics in Medicinal Chemistry, 2012, 12, 61-66.	2.1	6
81	Sarcoma spreads primarily through the vascular system: are there biomarkers associated with vascular spread?. Clinical and Experimental Metastasis, 2012, 29, 757-773.	3.3	26
82	Ulceration and stage are predictive of interferon efficacy in melanoma: Results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. European Journal of Cancer, 2012, 48, 218-225.	2.8	182
83	Recurrence and prognostic factors in patients with aggressive fibromatosis. The role of radical surgery and its limitations. World Journal of Surgical Oncology, 2012, 10, 184.	1.9	32
84	The role of BRAF V600 mutation in melanoma. Journal of Translational Medicine, 2012, 10, 85.	4.4	563
85	Alternatives for the treatment of local advanced disease: electrochemotherapy, limb perfusion, limb infusion, intralesional IL2. What is the role?. Dermatologic Therapy, 2012, 25, 443-451.	1.7	10
86	EORTC Melanoma Group achievements. European Journal of Cancer, Supplement, 2012, 10, 112-119.	2.2	0
87	Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. Lancet Oncology, The, 2012, 13, 879-886.	10.7	273
88	The cost of unresectable stage III or stage IV melanoma in Italy. Journal of Experimental and Clinical Cancer Research, 2012, 31, 91.	8.6	25
89	lpilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy. Cancer Immunology, Immunotherapy, 2012, 61, 41-48.	4.2	118
90	Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with <i>BRAF^{V600E}</i> -mutated melanoma Journal of Clinical Oncology, 2012, 30, 8502-8502.	1.6	86

#	Article	IF	CITATIONS
91	Phase II multicenter trial of ipilimumab combined with fotemustine in patients with metastatic melanoma: The Italian Network for Tumor Biotherapy (NIBIT)-M1 trial Journal of Clinical Oncology, 2012, 30, 8513-8513.	1.6	5
92	The NIBIT-M1 trial: Activity of ipilimumab plus fotemustine in patients with melanoma and brain metastases Journal of Clinical Oncology, 2012, 30, 8529-8529.	1.6	7
93	Randomized phase III trial of intravenous (IV) versus hepatic intra-arterial (HIA) fotemustine in patients with liver metastases from uveal melanoma: Final results of the EORTC 18021 study Journal of Clinical Oncology, 2012, 30, 8532-8532.	1.6	7
94	Long-termÂcure after complete resection and adjuvant immunotherapy for distant melanoma metastases Journal of Clinical Oncology, 2012, 30, 8534-8534.	1.6	1
95	Surgery in stage IV melanoma patients: Results from a single institution Journal of Clinical Oncology, 2012, 30, e19035-e19035.	1.6	3
96	Vulvar melanoma: A monocentric retrospective study on 29 cases Journal of Clinical Oncology, 2012, 30, e19036-e19036.	1.6	0
97	Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma. New England Journal of Medicine, 2011, 364, 2517-2526.	27.0	4,074
98	The immunological era in melanoma treatment: new challenges for heat shock protein-based vaccine in the advanced disease. Expert Opinion on Biological Therapy, 2011, 11, 1395-1407.	3.1	8
99	Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation. New England Journal of Medicine, 2011, 364, 2507-2516.	27.0	6,976
100	Diagnostic and therapeutic imaging for cancer: Therapeutic considerations and future directions. Journal of Surgical Oncology, 2011, 103, 587-601.	1.7	18
101	Treatment of melanoma metastases in a limb by isolated limb perfusion and isolated limb infusion. Journal of Surgical Oncology, 2011, 104, 397-404.	1.7	37
102	Local and intralesional therapy of inâ€ŧransit melanoma metastases. Journal of Surgical Oncology, 2011, 104, 391-396.	1.7	77
103	Prognosis in Patients With Sentinel Node–Positive Melanoma Is Accurately Defined by the Combined Rotterdam Tumor Load and Dewar Topography Criteria. Journal of Clinical Oncology, 2011, 29, 2206-2214.	1.6	195
104	Pelvic sentinel lymph node biopsy in melanoma patients: is it worthwhile?. Melanoma Research, 2010, 20, 133-137.	1.2	12
105	Serum concentrations of pegylated interferon α-2b in patients with resected stage III melanoma receiving adjuvant pegylated interferon α-2b in a randomized phase III trial (EORTC 18991). Cancer Chemotherapy and Pharmacology, 2010, 65, 671-677.	2.3	21
106	Anti–CTLA-4 Antibody Adjuvant Therapy in Melanoma. Seminars in Oncology, 2010, 37, 455-459.	2.2	37
107	Electrochemotherapy for cutaneous and subcutaneous tumor lesions: a novel therapeutic approach. Dermatologic Therapy, 2010, 23, 651-661.	1.7	123
108	Phase III Trial Comparing Adjuvant Treatment With Pegylated Interferon Alfa-2b Versus Observation: Prognostic Significance of Autoantibodies—EORTC 18991. Journal of Clinical Oncology, 2010, 28, 2460-2466.	1.6	69

#	Article	IF	CITATIONS
109	Reply to F. Janku et al. Journal of Clinical Oncology, 2010, 28, e17-e18.	1.6	9
110	Large Randomized Study of Thymosin α 1, Interferon Alfa, or Both in Combination With Dacarbazine in Patients With Metastatic Melanoma. Journal of Clinical Oncology, 2010, 28, 1780-1787.	1.6	62
111	Radio-guided ultrasound lymph node localization: feasibility of a new technique for localizing and excising nonpalpable lymph nodes ultrasound suspicious for melanoma metastases. Melanoma Research, 2010, 20, 197-202.	1.2	9
112	Adjuvant Therapy With Pegylated Interferon Alfa-2b Versus Observation in Resected Stage III Melanoma: A Phase III Randomized Controlled Trial of Health-Related Quality of Life and Symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group. Journal of Clinical Oncology, 2009, 27, 2916-2923.	1.6	119
113	HSPPC-96 vaccine in metastatic melanoma patients: from the state of the art to a possible future. Expert Review of Vaccines, 2009, 8, 1513-1526.	4.4	16
114	Oncophage [®] (vitespen [®]) - Heat shock protein peptide complex 96-based vaccines in melanoma: How far we are, how far we can get?. Hum Vaccin, 2009, 5, 727-737.	2.4	13
115	EANM-EORTC general recommendations for sentinel node diagnostics in melanoma. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 1713-1742.	6.4	159
116	Clinical Considerations on Sentinel Node Biopsy in Melanoma from an Italian Multicentric Study on 1,313 Patients (SOLISM–IMI). Annals of Surgical Oncology, 2009, 16, 2018-2027.	1.5	121
117	Desmoid Tumors of the Anterior Abdominal Wall: Results from a Monocentric Surgical Experience and Review of the Literature. Annals of Surgical Oncology, 2009, 16, 1642-1649.	1.5	48
118	Vitamin D and skin cancer: A meta-analysis. European Journal of Cancer, 2009, 45, 634-641.	2.8	113
119	Circulating melanoma cells and distant metastasis-free survival in stage III melanoma patients with or without adjuvant interferon treatment (EORTC 18991 side study). European Journal of Cancer, 2009, 45, 3189-3197.	2.8	48
120	Clinical genetic testing for familial melanoma in Italy: A cooperative study. Journal of the American Academy of Dermatology, 2009, 61, 775-782.	1.2	45
121	Cutaneous melanoma in the elderly. Melanoma Research, 2009, 19, 125-134.	1.2	19
122	Ilioinguinal Dissection for Melanoma. , 2009, , 223-228.		0
123	Practical guidelines for the management of interferonâ€Î±â€2b side effects in patients receiving adjuvant treatment for melanoma. Cancer, 2008, 112, 982-994.	4.1	116
124	Dendritic cell sarcoma: An analytic overview of the literature and presentation of original five cases. Critical Reviews in Oncology/Hematology, 2008, 65, 1-7.	4.4	86
125	Oncophage: step to the future for vaccine therapy in melanoma. Expert Opinion on Biological Therapy, 2008, 8, 1973-1984.	3.1	18
126	Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet, The, 2008, 372, 117-126.	13.7	620

#	Article	IF	CITATIONS
127	Phase III Comparison of Vitespen, an Autologous Tumor-Derived Heat Shock Protein gp96 Peptide Complex Vaccine, With Physician's Choice of Treatment for Stage IV Melanoma: The C-100-21 Study Group. Journal of Clinical Oncology, 2008, 26, 955-962.	1.6	238
128	Genomic rearrangements of the CDKN2A locus are infrequent in Italian malignant melanoma families without evidence of CDKN2A/CDK4 point mutations. Melanoma Research, 2008, 18, 431-437.	1.2	9
129	Modification of lymphoscintigraphic sentinel node identification before and after excisional biopsy of primary cutaneous melanoma. Melanoma Research, 2008, 18, 373-377.	1.2	9
130	Anti-CTLA4 Monoclonal Antibody Ipilimumab in the Treatment of Metastatic Melanoma: Recent Findings. Recent Patents on Anti-Cancer Drug Discovery, 2008, 3, 105-113.	1.6	24
131	Long-Term Protective Effect of Mature DC-LAMP+ Dendritic Cell Accumulation in Sentinel Lymph Nodes Containing Micrometastatic Melanoma. Clinical Cancer Research, 2007, 13, 3825-3830.	7.0	67
132	Cutaneous melanoma: digital dermoscopy -essential tool for positive diagnosis. Journal of Cellular and Molecular Medicine, 2006, 10, 991-994.	3.6	9
133	Primary and recurrent retroperitoneal soft tissue sarcoma: Prognostic factors affecting survival. Journal of Surgical Oncology, 2006, 93, 456-463.	1.7	22
134	Mitf regulation of Dia1 controls melanoma proliferation and invasiveness. Genes and Development, 2006, 20, 3426-3439.	5.9	495
135	The impact of lymphoscintigraphy technique on the outcome of sentinel node biopsy in 1,313 patients with cutaneous melanoma: an Italian Multicentric Study (SOLISM-IMI). Journal of Nuclear Medicine, 2006, 47, 234-41.	5.0	31
136	Update: current management issues in malignant melanoma. Melanoma Research, 2005, 15, 319-324.	1.2	13
137	The role of ultrasound of sentinel nodes in the pre- and post-operative evaluation of stage I melanoma patients. Melanoma Research, 2005, 15, 191-198.	1.2	34
138	Pulsed Dose-Rate Perioperative Interstitial Brachytherapy for Soft Tissue Sarcomas of the Extremities and Skeletal Muscles of the Trunk. Annals of Surgical Oncology, 2005, 12, 935-942.	1.5	17
139	Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial. Lancet, The, 2005, 366, 1189-1196.	13.7	310
140	Heat Shock Proteins and Their Use as Anticancer Vaccines. Clinical Cancer Research, 2004, 10, 8142-8146.	7.0	62
141	Heat shock proteins: biological functions and clinical application as personalized vaccines for human cancer. Cancer Immunology, Immunotherapy, 2004, 53, 227-233.	4.2	116
142	Vaccination of Metastatic Melanoma Patients With Autologous Tumor-Derived Heat Shock Protein gp96-Peptide Complexes: Clinical and Immunologic Findings. Journal of Clinical Oncology, 2002, 20, 4169-4180.	1.6	361
143	Surgical techniques of melanoma and sentinel node biopsy. Seminars in Oncology, 2002, 29, 328-335.	2.2	13
144	EPILUMINESCENCE MICROSCOPY FEATURES OF MELANOMA IN RELATION TO TUMOR THICKNESS. Dermatologic Clinics, 2001, 19, 285-297.	1.7	4

Alessandro A E Testori

#	Article	IF	CITATIONS
145	Sentinel Lymph Node Biopsy in Cutaneous Melanoma: The WHO Melanoma Program Experience. Annals of Surgical Oncology, 2000, 7, 469-474.	1.5	318
146	Sentinel node localization in cutaneous melanoma: lymphoscintigraphy with colloids and antibody fragments versus blue dye mapping. European Journal of Nuclear Medicine and Molecular Imaging, 1998, 25, 1489-1494.	6.4	39
147	Coming of age in culture. Experimental Gerontology, 1996, 31, 7-12.	2.8	37
148	The helix-loop-helix protein Id-1 and a retinoblastoma protein binding mutant of SV40 T antigen synergize to reactivate DNA synthesis in senescent human fibroblasts. Genesis, 1996, 18, 161-172.	2.1	71
149	The helixâ€loopâ€helix protein Idâ€1 and a retinoblastoma protein binding mutant of SV40 T antigen synergize to reactivate DNA synthesis in senescent human fibroblasts. Genesis, 1996, 18, 161-172.	2.1	1
150	Brain and testis selective expression of the glutathione S-transferase Yb3 subunit is governed by tandem direct repeat octamer motifs in the 5′-flanking region of its gene. Molecular Brain Research, 1995, 28, 37-46.	2.3	5
151	Acral Lentiginous Melanoma. The Journal of Dermatologic Surgery and Oncology, 1994, 20, 817-822.	0.8	54
152	Direct cloning of unmodified PCR products by exploiting an engineered restriction site. Gene, 1994, 143, 151-152.	2.2	19
153	Mucinous Carcinoma of the Breast. American Journal of Surgical Pathology, 1994, 18, 702-711.	3.7	92
154	Argyrophilia and Granin (Chromogranin/Secretogranin) Expression in Female Breast Carcinomas Their Relationship to Survival and Other Disease Parameters. American Journal of Surgical Pathology, 1992, 16, 561-576.	3.7	53
155	<i>In vivo</i> SPECTROPHOTOMETRIC EVALUATION OF NEOPLASTIC AND NONâ€NEOPLASTIC SKIN PIGMENTED LESIONS–I. REFLECTANCE MEASUREMENTS. Photochemistry and Photobiology, 1991, 53, 77-84.	2.5	79
156	Prognostic significance of her-2/neu expression in breast cancer and its relationship to other prognostic factors. International Journal of Cancer, 1991, 49, 44-49.	5.1	250
157	Comparison of long-term survival of 1986 consecutive patients with breast cancer treated at the national cancer institute of milano, italy (1971 to 1972 and 1977 to 1978). Cancer, 1991, 68, 427-434.	4.1	11
158	Long-Term Survival and Prognostic Factors for 2170 Breast Cancer Patients Treated at Two Cancer Centers: (Milan and Houston). Tumori, 1989, 75, 123-131.	1.1	12
159	Analysis of germline VEGF-A SNPs allows the identification of a subgroup of ATA low-intermediate risk DTC (differentiated thyroid cancer) patients with poor probability to develop recurrences. Endocrine Abstracts, 0, , .	0.0	1